Evidence / Albertazzi et al. · 2005
Short crossover trial of genistein and hot flushes
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Randomized, placebo-controlled crossover trial.
- Product relevance
- Ingredient research involving genistein.
- Sample or population
- 100 postmenopausal women.
- Studied dose
- 90 mg/day of pure genistein or placebo.
- Duration
- Six weeks per crossover period.
- Finding
- The trial reported a difference favouring genistein for hot flushes among women with higher baseline symptom scores. Changes in the measured bone turnover markers were not statistically significant.
- Limitations
- The symptom result came from a subgroup and each period was short. The dose and preparation differ from S-EQUOL PLUS.
- Study quality
- The outcomes, study design and limitations were reviewed. No formal risk-of-bias rating was assigned for this summary.
- Funding and disclosures
- Funding and conflicts were not verified from the PubMed abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.
Licensed product information
S-EQUOL PLUS · NPN 80143622
May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).